Featured Research

from universities, journals, and other organizations

Economic evaluation of an osteoporosis screening campaign using FRAX

Date:
April 3, 2014
Source:
International Osteoporosis Foundation
Summary:
An osteoporosis screening strategy using FRAX as a pre-screening tool is cost-effective if the follow up of the screening and medication adherence are optimized, research shows. FRAX (WHO Fracture Risk Assessment Tool) is a widely used algorithm to determine 10-year risk of fracture based on an individual's risk factors.

In new research presented at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, investigators showed that an osteoporosis screening strategy using FRAX as a pre-screening tool is cost-effective if the follow up of the screening and medication adherence are optimized. FRAX (WHO Fracture Risk Assessment Tool) is a widely used algorithm to determine 10-year risk of fracture based on an individual's risk factors.

Researchers from the University of Maastricht and the University of Liège evaluated the cost-effectiveness of an osteoporosis screening campaign in the Province of Liège (Belgium). A previously validated microsimulation model was used to estimate the incremental cost-effectiveness ratio (ICER), expressed in costs (in €) per quality-adjusted life-year gained (QALY) gained, of the screening/treatment strategy versus no intervention. The screening/treatment strategy consisted of pre-screening using FRAX, followed by a bone densitometry for patients with a positive FRAX result and combined with a 5-year branded alendronate therapy for women diagnosed with osteoporosis (bone mineral density (BMD) T-score≤−2.5).

The ICER for the screening/treatment strategy versus no intervention in the whole population (mean age=60 years) was estimated at €66,665 and €39,504 per QALY gained assuming real-world and full adherence respectively. ICERs decreased to €55,517 and €28,520 in the population aged over 60 years (mean age= 65 years). The ICER of the screening strategy decreases when improving the follow-up of a positive screening and when increasing fracture risk. Using the price of generic alendronate, the cost-effectiveness improved to €50,880 and €32,293 assuming real-world and full adherence, respectively.

The authors therefore conclude that the osteoporosis screening strategy is cost-effective if the follow up of the screening and medication adherence are optimized. Therefore, BMD should be performed in all individuals with posi¬tive FRAX score; individuals having a positive BMD diagnosis should be treated and adherence to therapy should be optimized.

Doctor Mickaël Hiligsmann, Assistant Professor in Health Economics and Health Technology Assessment at Maastricht University and Invited Professor at University of Liège, stated, "To further improve the cost-effectiveness of the screening strategy, we suggest targeting screening on women with one or more clinical risk factors, or on women aged 65 years and older."


Story Source:

The above story is based on materials provided by International Osteoporosis Foundation. Note: Materials may be edited for content and length.


Cite This Page:

International Osteoporosis Foundation. "Economic evaluation of an osteoporosis screening campaign using FRAX." ScienceDaily. ScienceDaily, 3 April 2014. <www.sciencedaily.com/releases/2014/04/140403084452.htm>.
International Osteoporosis Foundation. (2014, April 3). Economic evaluation of an osteoporosis screening campaign using FRAX. ScienceDaily. Retrieved August 21, 2014 from www.sciencedaily.com/releases/2014/04/140403084452.htm
International Osteoporosis Foundation. "Economic evaluation of an osteoporosis screening campaign using FRAX." ScienceDaily. www.sciencedaily.com/releases/2014/04/140403084452.htm (accessed August 21, 2014).

Share This




More Health & Medicine News

Thursday, August 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) — An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) — Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) — It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com
Lost Brain Cells To Blame For Sleep Problems Among Seniors

Lost Brain Cells To Blame For Sleep Problems Among Seniors

Newsy (Aug. 21, 2014) — According to a new study, elderly people might have trouble sleeping because of the loss of a certain group of neurons in the brain. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins